Cor Pulmonale — Right heart strain and cor pulmonale concepts (intro)

The relationship between lung disease and heart failure has been recognized for centuries, though the precise pathophysiological mechanisms were not elucidated until the twentieth century. The term cor pulmonale — literally pulmonary heart — describes structural and functional changes in the right ventricle that arise secondary to diseases affecting the pulmonary vasculature or the lung parenchyma. Unlike left-sided heart failure, which typically originates from systemic hypertension or coronary artery disease, cor pulmonale reflects a fundamentally different hemodynamic burden: the right ventricle must pump against an abnormally elevated pulmonary vascular resistance. Understanding this entity is critical for healthcare professionals because it represents one of the most common cardiac consequences of chronic respiratory disease and carries significant morbidity and mortality.

With chronic obstructive pulmonary disease (COPD) affecting over 380 million people worldwide and interstitial lung diseases growing in prevalence, the clinical question that drives this lesson remains urgent: How do chronic pulmonary conditions impose a hemodynamic burden on the right ventricle, and at what point does compensatory adaptation give way to overt heart failure?

To understand cor pulmonale, one must appreciate the fundamental differences between the right and left ventricles and the circulatory beds they serve. The right ventricle (RV) is a thin-walled, crescent-shaped chamber that normally operates as a volume pump in a low-pressure, low-resistance pulmonary circuit. Mean pulmonary artery pressure (mPAP) at rest is approximately 14 mmHg, compared to a mean systemic arterial pressure of roughly 93 mmHg. This enormous difference reflects the fact that the pulmonary vasculature is a highly compliant, low-resistance system. When this resistance rises chronically — whether from hypoxic vasoconstriction, vascular remodeling, or parenchymal destruction — the right ventricle must generate greater wall tension, initiating a cascade of hypertrophy, dilation, and eventual failure.

The diagram above illustrates why cor pulmonale is fundamentally a disease of the pulmonary vasculature acting upon the right heart. The initiating event is always a process that reduces the cross-sectional area of the pulmonary vascular bed or actively constricts pulmonary arterioles. In COPD, emphysematous destruction of alveolar walls obliterates the capillary network, while chronic hypoxia triggers sustained HPV. In interstitial lung disease (ILD), fibrotic tissue replaces normal parenchyma and compresses or obliterates pulmonary capillaries. In chronic thromboembolic disease, organized clot physically obstructs the pulmonary arterial lumen. Despite differing etiologies, each condition converges on the same hemodynamic result: elevated pulmonary vascular resistance and increased right ventricular afterload.

Although cor pulmonale is diagnosed clinically and echocardiographically rather than through mathematical calculation, the hemodynamic principles governing pulmonary pressure and right ventricular performance can be expressed quantitatively. Understanding these relationships clarifies why even modest increases in pulmonary vascular resistance produce disproportionate effects on the right ventricle.

Cor pulmonale can be classified by temporal course — acute versus chronic — and by the site of pathology within the respiratory system. Acute cor pulmonale develops over hours to days, most commonly from massive pulmonary embolism, which suddenly obstructs a large portion of the pulmonary vascular bed and causes acute RV pressure overload and dilation. Chronic cor pulmonale develops over months to years as progressive pulmonary vascular disease or parenchymal destruction slowly raises PVR. The chronic form allows time for compensatory RV hypertrophy, which may maintain cardiac output for a prolonged period before decompensation occurs.

Among the chronic etiologies, COPD accounts for approximately 80–90% of all cases of cor pulmonale in clinical practice, making it by far the most common cause. The pathophysiology in COPD is multifactorial: emphysematous capillary bed destruction reduces vascular cross-sectional area, chronic alveolar hypoxia drives sustained HPV, hypercapnia and respiratory acidosis augment vasoconstriction, and secondary polycythemia increases blood viscosity. These overlapping mechanisms explain why patients with severe COPD (GOLD stage III–IV) are at particularly high risk. Importantly, the presence of cor pulmonale in COPD is associated with a markedly worse prognosis — five-year survival drops from approximately 70% to less than 30% once signs of right heart failure become apparent.

Consider the following clinical scenario: A 68-year-old man with GOLD stage IV COPD presents with worsening dyspnea, peripheral edema, and an elevated JVP. Right heart catheterization reveals the following: cardiac output (CO) = 4.0 L/min, mean pulmonary artery pressure (mPAP) = 38 mmHg, pulmonary capillary wedge pressure (PCWP) = 10 mmHg. We will calculate PVR and interpret the findings.

One of the most clinically important skills is distinguishing cor pulmonale (right heart failure from pulmonary causes) from left-sided heart failure. While both conditions may present with dyspnea, the underlying pathophysiology, physical examination findings, and treatment strategies differ fundamentally. Clinicians must also recognize that left heart failure can secondarily cause pulmonary hypertension (postcapillary PH), but this is explicitly excluded from the definition of cor pulmonale.

Cor pulmonale exists within the broader framework of pulmonary hypertension (PH) classification. The current WHO/ESC classification system divides PH into five groups based on etiology and mechanism. Cor pulmonale most directly corresponds to Group 3: PH due to lung diseases and/or hypoxia, though the term can also apply to Group 4 (chronic thromboembolic PH) and certain Group 5 conditions. Understanding this classification framework is essential for advanced study, as it dictates therapeutic strategy and prognosis. For instance, pulmonary vasodilator therapies (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues) that are mainstays in Group 1 pulmonary arterial hypertension (PAH) have shown limited efficacy — and potential harm — in Group 3 PH due to worsening ventilation-perfusion mismatch.

As you advance in your studies, you will explore how molecular signaling pathways — including the nitric oxide–cyclic GMP pathway, the endothelin system, and prostacyclin signaling — contribute to the vascular remodeling that underlies pulmonary hypertension in all its forms. These molecular targets underpin the pharmacotherapy used in Group 1 PAH and represent active areas of translational research for Group 3 PH and cor pulmonale.